Cancer Chemotherapy and Pharmacology

, Volume 62, Issue 5, pp 779–786

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

  • Jian-Feng Lu
  • Rene Bruno
  • Steve Eppler
  • William Novotny
  • Bert Lum
  • Jacques Gaudreault
Original Article



To characterize the population pharmacokinetics of bevacizumab and the influence of demographic factors, disease severity, and concomitantly used chemotherapy agents on it’s pharmacokinetic behavior.

Patients and methods

Data from eight clinical trials with bevacizumab administered by intravenous infusion were included. A total of 4,629 bevacizumab concentrations from 491 patients with solid tumors, who received bevacizumab doses ranging from 1 to 20 mg/kg at a dosing frequency ranging from weekly to every 3 weeks, were analyzed using a nonlinear mixed-effects modeling approach (NONMEM).


The best structural model was a two-compartment model with first-order elimination. In the final model, estimated clearance (CL) and central compartment volume of distribution (Vc) were 0.207 L/day and 2.39 L for a typical female. The terminal half-life estimate was ∼20 days for both men and women. Body weight and gender were the most significant covariates to explain interpatient variability for CL and Vc. Clearance was 26% faster in men than in women. Patients with low serum albumin and high serum alkaline phosphatase had 19 and 23% faster CL, respectively, than a typical patient. Consistent with the long elimination half life, simulations showed that similar steady-state exposures can be maintained when the weekly mg/kg dose rate is maintained, therefore allowing administration of bevacizumab to coincide with the frequency of administration of the cytotoxic agents.


The PK parameters were consistent with those of other IgG molecules. The results support dosing bevacizumab on a once every 2 weeks or once every 3 weeks dosing schedule on a mg/kg basis.


Population pharmacokinetics Bevacizumab Monoclonal antibody Covariate effect Dosing schedule 


  1. 1.
    Avastin Biological License Application (BLA) (2003) Data on file Genentech, Inc., South San FranciscoGoogle Scholar
  2. 2.
    AVASTIN (package insert) (2004) Genentech, Inc., South San Francisco, DecemberGoogle Scholar
  3. 3.
    Beal SL, Sheiner LB (1992) NONMEM User’s Guide. NONMEM Project Group. University of California, San FranciscoGoogle Scholar
  4. 4.
    Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361–369PubMedCrossRefGoogle Scholar
  5. 5.
    Giantonio BJ, Catalano PJ, Meropol NJ et al (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol [ASCO Annual Meeting Proceedings. 23 (no. 16S, Part I of II, June 1 Supplement), 2005:2]Google Scholar
  6. 6.
    Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669076Google Scholar
  7. 7.
    Gobburu JVS, Lawrence J (2002) Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharmacol Res 19:9–28Google Scholar
  8. 8.
    Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R et al (2002) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850Google Scholar
  9. 9.
    Hsei VC, Novotny WF, Margolin K et al (2001) Population pharmacokinetic (PK) analysis of bevacizumab (BV) in cancer subjects. Proc Am Soc Clin Oncol 20 (abstract 272)Google Scholar
  10. 10.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  11. 11.
    Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191PubMedCrossRefGoogle Scholar
  12. 12.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65PubMedCrossRefGoogle Scholar
  13. 13.
    Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668PubMedCrossRefGoogle Scholar
  14. 14.
    Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G et al (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19:851–856PubMedGoogle Scholar
  15. 15.
    Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799PubMedCrossRefGoogle Scholar
  16. 16.
    Reese D, Frohlich D, Bok R, Corry M, Novotny W, Homgren E, Small E (1999) A Phase II trial of humanized monoclonal antivascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 18:1355aGoogle Scholar
  17. 17.
    Sandler AB, Gray R, Brahmer J et al (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol [ASCO Annual Meeting Proceedings, vol 23, no 16S, Part I of II (June 1 Supplement), 2005:4]Google Scholar
  18. 18.
    Shen BQ et al (2006) Hepatic dysfunction resulting from common bile duct ligation did not affect the pharmacokinetics of bevacizumab (Avastin) in Sprague–Dawley rats. In: Proceedings AACR, vol 47, p 731Google Scholar
  19. 19.
    Trang JM (1992) Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Ferraiolo BL, Mohler MA, Gloff CA (eds) Protein pharmacokinetics and metabolism. Pharmaceutical biotechnology, vol 1. Plenum Press, New York, pp 223–270Google Scholar
  20. 20.
    Wahlby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231–252PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Jian-Feng Lu
    • 1
  • Rene Bruno
    • 1
    • 4
  • Steve Eppler
    • 1
  • William Novotny
    • 2
  • Bert Lum
    • 1
  • Jacques Gaudreault
    • 1
    • 3
  1. 1.Department of Pharmacokinetic and Pharmacodynamic SciencesGenentech, Inc.South San FranciscoUSA
  2. 2.Department of Clinical SciencesGenentech, Inc.South San FranciscoUSA
  3. 3.F Hoffmann-La Roche, LtdBaselSwitzerland
  4. 4.Pharsight CorporationMountain ViewUSA

Personalised recommendations